492 related articles for article (PubMed ID: 17716136)
1. Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis.
Marsh JN; Senpan A; Hu G; Scott MJ; Gaffney PJ; Wickline SA; Lanza GM
Nanomedicine (Lond); 2007 Aug; 2(4):533-43. PubMed ID: 17716136
[TBL] [Abstract][Full Text] [Related]
2. Novel and emerging therapies: thrombus-targeted fibrinolysis.
Lippi G; Mattiuzzi C; Favaloro EJ
Semin Thromb Hemost; 2013 Feb; 39(1):48-58. PubMed ID: 23034825
[TBL] [Abstract][Full Text] [Related]
3. Preparation of Peptide and Recombinant Tissue Plasminogen Activator Conjugated Poly(Lactic-Co-Glycolic Acid) (PLGA) Magnetic Nanoparticles for Dual Targeted Thrombolytic Therapy.
Chen HA; Ma YH; Hsu TY; Chen JP
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32294917
[TBL] [Abstract][Full Text] [Related]
4. Turbulent axially directed flow of plasma containing rt-PA promotes thrombolysis of non-occlusive whole blood clots in vitro.
Tratar G; Blinc A; Strukelj M; Mikac U; Sersa I
Thromb Haemost; 2004 Mar; 91(3):487-96. PubMed ID: 14983224
[TBL] [Abstract][Full Text] [Related]
5. Delivery of tissue plasminogen activator and streptokinase magnetic nanoparticles to target vascular diseases.
Tadayon A; Jamshidi R; Esmaeili A
Int J Pharm; 2015 Nov; 495(1):428-438. PubMed ID: 26363110
[TBL] [Abstract][Full Text] [Related]
6. Fibrin clot lysis by thrombolytic agents is impaired in newborns due to a low plasminogen concentration.
Andrew M; Brooker L; Leaker M; Paes B; Weitz J
Thromb Haemost; 1992 Sep; 68(3):325-30. PubMed ID: 1440499
[TBL] [Abstract][Full Text] [Related]
7. Pro- and antifibrinolytic effects of ultrasound on streptokinase-induced thrombolysis.
Nilsson AM; Odselius R; Roijer A; Olsson SB
Ultrasound Med Biol; 1995; 21(6):833-40. PubMed ID: 8571471
[TBL] [Abstract][Full Text] [Related]
8. Streptokinase entrapment in interdigitation-fusion liposomes improves thrombolysis in an experimental rabbit model.
Perkins WR; Vaughan DE; Plavin SR; Daley WL; Rauch J; Lee L; Janoff AS
Thromb Haemost; 1997 Jun; 77(6):1174-8. PubMed ID: 9241753
[TBL] [Abstract][Full Text] [Related]
9. Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential.
Onundarson PT; Francis CW; Marder VJ
J Lab Clin Med; 1992 Jul; 120(1):120-8. PubMed ID: 1613318
[TBL] [Abstract][Full Text] [Related]
10. Elongated Plant Virus-Based Nanoparticles for Enhanced Delivery of Thrombolytic Therapies.
Pitek AS; Wang Y; Gulati S; Gao H; Stewart PL; Simon DI; Steinmetz NF
Mol Pharm; 2017 Nov; 14(11):3815-3823. PubMed ID: 28881141
[TBL] [Abstract][Full Text] [Related]
11. The effect of flow on lysis of plasma clots in a plasma environment.
Sakharov DV; Rijken DC
Thromb Haemost; 2000 Mar; 83(3):469-74. PubMed ID: 10744155
[TBL] [Abstract][Full Text] [Related]
12. [Binding of an acylated plasminogen activator-streptokinase complex with fibrin and the fibrinolytic response in vitro].
Aĭsina RB; Zhitkova IuV; Varfolomeev SD
Vopr Med Khim; 1994; 40(3):31-5. PubMed ID: 8079435
[TBL] [Abstract][Full Text] [Related]
13. Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents.
Lam SC; Dieter JP; Strebel LC; Taylor TM; Muscolino G; Feinberg H; Le Breton GC
J Pharmacol Exp Ther; 1991 Dec; 259(3):1371-8. PubMed ID: 1762085
[TBL] [Abstract][Full Text] [Related]
14. Prourokinase mutant that induces highly effective clot lysis without interfering with hemostasis.
Liu JN; Liu JX; Liu Bf BF; Sun Z; Zuo JL; Zhang Px PX; Zhang J; Chen Yh YH; Gurewich V
Circ Res; 2002 Apr; 90(7):757-63. PubMed ID: 11964367
[TBL] [Abstract][Full Text] [Related]
15. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
[TBL] [Abstract][Full Text] [Related]
16. [Effect of diagnostic ultrasound-mediated microbubble contrast and urokinase on augmentation thrombolysis and optimization of the major parameters: an in vitro study].
Yu QM; Wang H; Meng WT; Li YQ; Yang JR; Li J; Zhou X; Niu T
Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 May; 43(3):451-7. PubMed ID: 22812257
[TBL] [Abstract][Full Text] [Related]
17. The molecular basis of thrombolysis and its clinical application in stroke.
Murray V; Norrving B; Sandercock PA; Terént A; Wardlaw JM; Wester P
J Intern Med; 2010 Feb; 267(2):191-208. PubMed ID: 20175866
[TBL] [Abstract][Full Text] [Related]
18. [The absence of a procoagulant effect after TNK-t-PA: a comparison with streptokinase and rt-PA].
De Marco E; Andreotti F; van de Greef W; Quaranta G; Biasucci LM; Kol A; Maseri A; Rebuzzi AG
Cardiologia; 1998 Nov; 43(11):1209-13. PubMed ID: 9922587
[TBL] [Abstract][Full Text] [Related]
19. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.
Varin R; Mirshahi S; Mirshahi P; Klein C; Jamshedov J; Chidiac J; Perzborn E; Mirshahi M; Soria C; Soria J
Thromb Res; 2013 Mar; 131(3):e100-9. PubMed ID: 23313382
[TBL] [Abstract][Full Text] [Related]
20. Co-ordinated spatial propagation of blood plasma clotting and fibrinolytic fronts.
Zhalyalov AS; Panteleev MA; Gracheva MA; Ataullakhanov FI; Shibeko AM
PLoS One; 2017; 12(7):e0180668. PubMed ID: 28686711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]